Business Context and Reporting Period
Company: The Cooper Companies, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Three and six months ended April 30, 1996
Business Overview: The Company develops, manufactures, and markets healthcare products (contact lenses, surgical instruments) and provides healthcare services through psychiatric facilities (Hospital Group of America, Inc. or HGA).
Key Financial Metrics
| Metric (Six Months Ended Apr 30, 1996) | Value (in thousands) |
|---|---|
| Net Operating Revenue | $49,024 |
| Income from Operations | $5,774 |
| Net Income | $3,461 |
| Earnings Per Share (EPS) | $0.30 |
| Cash and Cash Equivalents (End of Period) | $1,894 |
| Net Cash Used by Operating Activities | $(7,358) |
| Total Debt (Current + Long-term) | $52,537 |
| Stockholders' Equity | $1,825 |
Margins: Gross profit margin for products was 70% for the six months ended April 30, 1996, compared to 67% in the prior year period. Service revenue profit margin was 3% for the six-month period.
Material Changes vs. Prior Period
- Revenue Growth: Net sales of products increased 15% ($3.8 million) year-over-year for the six-month period, driven by CooperVision (CVI) and CooperSurgical (CSI). Net service revenue decreased 8% due to managed care pressures and the expiration of management contracts.
- Profitability Surge: Income from operations increased 131% to $5.8 million, and Net Income increased to $3.5 million from $0.9 million in the prior year period. EPS rose from $0.08 to $0.30.
- Acquisition: Acquired Unimar, Inc. in April 1996 for $8 million (cash and notes), contributing $331,000 in sales for the quarter.
- R&D Reduction: Research and development expenses dropped significantly (from $1.9 million to $0.6 million) due to the discontinuation of specific drug and technology development projects.
- Equity Position: The Company returned to a positive stockholders' equity position ($1.8 million) from a deficit of $1.7 million at the end of the prior fiscal year.
Guidance, Outlook, and Risks
Management Outlook:
- Fiscal 1996 EPS: Anticipated to range from $1.00 to $1.10, including a projected 20-cent deferred tax benefit.
- Revenue: Expects double-digit growth driven by CVI's market share gains in toric lenses and CSI's integration of Unimar.
- HGA Performance: Expected to outperform 1995 results following a turnaround at Hampton Hospital.
Liquidity and Cash Flow:
- Operating cash flow was negative $7.4 million for the six months, primarily due to dispute settlements ($4.4 million), bonus payments ($2.0 million), and increased working capital ($4.2 million).
- Cash balances declined from $11.2 million to $1.9 million. The Company anticipates positive operating cash flows for the remainder of fiscal 1996.
Risks and Contingencies:
- Revenue pressure from managed care trends (lower daily rates, shorter stays).
- Dependence on state agencies for HGA revenue, which pay more slowly, increasing receivables.
- Forward-looking statements are subject to risks including litigation, interest rate changes, and acquisition costs.
Investor Verification Checklist
- Cash Burn Rate: Verify the sustainability of operations given the $7.4 million cash outflow from operations and the drop in cash reserves to under $2 million.
- Debt Obligations: Review the $49 million in long-term debt, including the 12% notes issued for the Unimar acquisition and the 10% Senior Subordinated Notes.
- Deferred Tax Benefit: Confirm the realization of the anticipated 20-cent per share deferred tax benefit included in the full-year guidance.
- Receivables Quality: Assess the $2.8 million increase in HGA receivables attributed to slower-paying state agencies.
- Acquisition Integration: Monitor the performance of the Unimar acquisition to ensure it meets the projected contribution to CSI's operating income.